secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001493152-24-029517
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001
--------------------------------------------------------------------------------

- Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).
- In patients receiving ≥3 doses, OS extended by 15.7 months (45.1 vs 29.4); HR 0.64.
- PARP inhibitor subgroup: median OS not reached in IMNN-001 arm vs 37.1 months; HR 0.41.
- PFS primary endpoint: 3-month improvement (14.9 vs 11.9); HR 0.79.
- Company plans registrational Phase 3 study to begin in Q1 2025; End-of-Phase 2 meeting with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/0001493152-24-029517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer